Almost three-fourths of patients with biochemically recurrent prostate cancer remained metastasis free at 5 years following salvage radiotherapy (sRT) informed by prostate-specific membrane antigen ...
Differences in incidence and clinicopathologic features of secondary bladder cancer after long-term follow-up of brachytherapy and radical prostatectomy for localized prostate cancer. Evaluation of ...
Global burden of prostate cancer in 38 OECD countries and its trend from 1990-2021: An Insight from the Global Burden of Disease study 2021. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Among prostate cancer patients with a luminal B subtype, the 5-year biochemical progression-free survival rate was 72% in the apalutamide group and 54% in the placebo group. Recurrent prostate cancer ...
The success rate of salvage radiation after prostatectomy differs by patients’ PSA. Only a subset of patients with biochemically recurrent prostate cancer after radical prostatectomy (RP) will develop ...
Deciding how to diagnose and treat prostate cancer has long been the subject of controversy and uncertainty. A prime example involves prostate-specific antigen (PSA) testing, a blood test for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results